NKMax Co Ltd
KOSDAQ:182400
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NKMax Co Ltd
Revenue
NKMax Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NKMax Co Ltd
KOSDAQ:182400
|
Revenue
₩7.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
12%
|
|
|
Celltrion Inc
KRX:068270
|
Revenue
₩4.2T
|
CAGR 3-Years
22%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Revenue
₩14.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Revenue
₩0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Revenue
₩215.9B
|
CAGR 3-Years
96%
|
CAGR 5-Years
38%
|
CAGR 10-Years
47%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Revenue
₩79.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
NKMax Co Ltd
Glance View
NKMAX Co., Ltd. engages in the development, manufacture, and sale of recombinant proteins and monoclonal antibodies. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2015-10-23. The firm is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The firm distributes its products within domestic market and to overseas markets.
See Also
What is NKMax Co Ltd's Revenue?
Revenue
7.9B
KRW
Based on the financial report for Dec 31, 2025, NKMax Co Ltd's Revenue amounts to 7.9B KRW.
What is NKMax Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
12%
Over the last year, the Revenue growth was -11%. The average annual Revenue growth rates for NKMax Co Ltd have been -11% over the past three years , -5% over the past five years , and 12% over the past ten years .
